Massmutual Trust Co. FSB ADV Has $608,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Posted by Joseph Griffin on Mar 19th, 2023

Massmutual Trust Co. FSB ADV increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,767 shares of the medical equipment provider’s stock after acquiring an additional 113 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Zimmer Biomet were worth $608,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Old North State Trust LLC acquired a new position in Zimmer Biomet in the third quarter valued at about $54,000. UBS Asset Management Americas Inc. increased its holdings in shares of Zimmer Biomet by 5.2% in the third quarter. UBS Asset Management Americas Inc. now owns 817,386 shares of the medical equipment provider’s stock worth $85,458,000 after acquiring an additional 40,317 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Zimmer Biomet in the second quarter worth about $882,000. Nicolet Advisory Services LLC increased its holdings in shares of Zimmer Biomet by 34.3% in the third quarter. Nicolet Advisory Services LLC now owns 2,544 shares of the medical equipment provider’s stock worth $272,000 after acquiring an additional 650 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Zimmer Biomet by 52.4% in the third quarter. Assetmark Inc. now owns 22,174 shares of the medical equipment provider’s stock worth $2,318,000 after acquiring an additional 7,621 shares in the last quarter. Institutional investors and hedge funds own 87.21% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $124.31 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.39 and a 12-month high of $135.05. The stock has a market cap of $26.11 billion, a price-to-earnings ratio of 113.01, a PEG ratio of 2.87 and a beta of 1.00. The business has a 50 day moving average of $125.21 and a 200-day moving average of $118.70. The company has a quick ratio of 0.97, a current ratio of 1.88 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH – Get Rating) last released its quarterly earnings data on Friday, February 3rd. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.05. Zimmer Biomet had a return on equity of 11.97% and a net margin of 3.33%. The company had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.76 billion. During the same period last year, the firm posted $1.95 earnings per share. The business’s revenue was up 2.7% on a year-over-year basis. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.04 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Investors of record on Wednesday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 28th. This represents a $0.96 annualized dividend and a yield of 0.77%. Zimmer Biomet’s payout ratio is currently 87.27%.

Analyst Ratings Changes

Several equities research analysts have issued reports on ZBH shares. Citigroup increased their price target on Zimmer Biomet from $116.00 to $130.00 and gave the stock a “neutral” rating in a report on Monday, December 12th. Morgan Stanley increased their price objective on Zimmer Biomet from $135.00 to $140.00 and gave the stock an “equal weight” rating in a report on Monday, February 6th. Loop Capital increased their price objective on Zimmer Biomet from $125.00 to $140.00 in a report on Monday, February 6th. Evercore ISI downgraded Zimmer Biomet from an “outperform” rating to an “inline” rating and set a $130.00 price objective for the company. in a report on Tuesday, January 3rd. Finally, Truist Financial increased their price objective on Zimmer Biomet from $135.00 to $137.00 and gave the stock a “hold” rating in a report on Monday, February 6th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $133.56.

Zimmer Biomet Profile

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.